Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
60-Word AI Digest
Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
Key Takeaways
- Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
- Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
- Click full coverage link below for the complete official dispatch.
Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
Original Publisher Attribution
This summary was curated from Livemint.